120 related articles for article (PubMed ID: 8873419)
1. Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant.
Suontaka AM; Akerblom O; Blombäck M; Eriksson L; Högman CF; Payrat JM
Vox Sang; 1996; 71(2):97-102. PubMed ID: 8873419
[TBL] [Abstract][Full Text] [Related]
2. Improved preservation of coagulation factors after pre-storage leukocyte depletion of whole blood.
Solheim BG; Flesland O; Brosstad F; Mollnes TE; Seghatchian J
Transfus Apher Sci; 2003 Oct; 29(2):133-9. PubMed ID: 12941351
[TBL] [Abstract][Full Text] [Related]
3. Half-strength citrate CPD and new additive solutions for improved blood preservation. I. Studies of six experimental solutions.
Högman CF; Eriksson L; Gong J; Payrat JM; Debrauwere J
Transfus Med; 1993 Mar; 3(1):43-50. PubMed ID: 8038896
[TBL] [Abstract][Full Text] [Related]
4. The stability of coagulation factors in stored blood.
Hondow JA; Russell WJ; Duncan BM; Lloyd JV
Aust N Z J Surg; 1982 Jun; 52(3):265-9. PubMed ID: 6954930
[TBL] [Abstract][Full Text] [Related]
5. Stability of red cell antigens and plasma coagulation factors stored in new formulation plastic blood containers.
Snyder EL; Hezzey A; Weirich F; Mosher DF; Davisson W; Buchholz DH
Transfusion; 1983; 23(1):49-53. PubMed ID: 6829059
[TBL] [Abstract][Full Text] [Related]
6. Storage of buffy coat preparations at 22 degrees C in plastic containers with different gas permeability.
Eriksson L; Eriksson G; Högman CF
Vox Sang; 1997; 73(2):74-80. PubMed ID: 9304775
[TBL] [Abstract][Full Text] [Related]
7. Shelf-life of bank blood and stored plasma with special reference to coagulation factors.
Nilsson L; Hedner U; Nilsson IM; Robertson B
Transfusion; 1983; 23(5):377-81. PubMed ID: 6414128
[TBL] [Abstract][Full Text] [Related]
8. Whole blood storage in citrate and phosphate solutions containing half-strength trisodium citrate: cellular and biochemical studies.
Mishler JM; Darley JH; Cederholm-Williams S; Wright G
J Pathol; 1978 Mar; 124(3):125-39. PubMed ID: 722376
[TBL] [Abstract][Full Text] [Related]
9. In vitro properties of red cells prepared from half-strength citrate CPD/RAS-2 (Erythro-sol) donations in PL-146 plastic.
Hornsey VS; MacDonald S; Drummond O; Bethel H; Walker B; Prowse CV
Transfus Med; 2000 Mar; 10(1):31-5. PubMed ID: 10760201
[TBL] [Abstract][Full Text] [Related]
10. Improved blood preservation with 0.5CPD erythro-sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood.
Solheim BG; Bergerud UE; Kjeldsen-Kragh J; Brosstad F; Mollnes TE; Högman CF; Eriksson L; Schutz R
Vox Sang; 1998; 74(3):168-75. PubMed ID: 9595644
[TBL] [Abstract][Full Text] [Related]
11. Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use.
Högman CF; Eriksson L; Gong J; Högman AB; Vikholm K; Debrauwere J; Payrat JM; Stewart M
Vox Sang; 1993; 65(4):271-8. PubMed ID: 8310679
[TBL] [Abstract][Full Text] [Related]
12. Effect of delayed refrigeration on plasma factors in whole blood collected in CPDA-2.
Sohmer PR; Bolin RB; Scott RL; Smith DJ
Transfusion; 1982; 22(6):488-90. PubMed ID: 6815841
[TBL] [Abstract][Full Text] [Related]
13. Studies on the procurement of blood coagulation factor VIII. In vitro studies on blood components prepared in half-strength citrate anticoagulant 18 hours after phlebotomy.
Griffin B; Bell K; Prowse C
Vox Sang; 1988; 55(1):9-13. PubMed ID: 3138819
[TBL] [Abstract][Full Text] [Related]
14. Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma.
Vermeer C; Soute BA; Ates G; Brummelhuis HG
Vox Sang; 1976; 30(1):1-22. PubMed ID: 1251567
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5CPD Erythro-Sol opti system.
Högman CF; Eriksson L; Wallvik J; Payrat JM
Vox Sang; 1997; 73(4):212-9. PubMed ID: 9407638
[TBL] [Abstract][Full Text] [Related]
16. Activation of blood coagulation, fibrinolytic and kallikrein systems during storage of plasma.
Blombäck M; Chmielewska J; Netré C; Akerblom O
Vox Sang; 1984; 47(5):335-42. PubMed ID: 6209855
[TBL] [Abstract][Full Text] [Related]
17. Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant.
Prowse C; Waterston YG; Dawes J; Farrugia A
Vox Sang; 1987; 52(4):257-64. PubMed ID: 3114954
[TBL] [Abstract][Full Text] [Related]
18. Buffy-coat-derived platelet concentrates prepared from half-strength citrate CPD and CPD whole-blood units. Comparison between three additive solutions: in vitro studies.
Gulliksson H; Eriksson L; Högman CF; Payrat JM
Vox Sang; 1995; 68(3):152-9. PubMed ID: 7625071
[TBL] [Abstract][Full Text] [Related]
19. Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells.
Farrugia A; Douglas S; James J; Whyte G
Vox Sang; 1992; 63(1):31-8. PubMed ID: 1413661
[TBL] [Abstract][Full Text] [Related]
20. An in vivo comparison of CPD and CPDA-2 preserved platelet concentrates after an 8-hour preprocess hold of whole blood.
Bolin RB; Cheney BA; Smith DJ; Gildengorin V; Shigekawa R
Transfusion; 1982; 22(6):491-5. PubMed ID: 7147328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
